PD-L1 Archives - BJBMS Viewpoints

September 23, 2021

Latest posts

[ August 25, 2021 ] 14th Bryan Warren School of Pathology: Soft tissue News
[ September 20, 2021 ] Vitiligo and hearing loss Author Summary
[ September 6, 2021 ] Call for emergency action to limit global temperature increases, restore biodiversity, and protect health News
[ September 3, 2021 ] 5th Urogenital Pathology Meeting News
[ September 2, 2021 ] Cranial nerve involvement in COVID-19 Author Summary
[ September 1, 2021 ] The Reviewer of the Month for September 2021: Dr. Adrian Montano Reviewer of the month

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

July 22, 2017 0

Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

June 9, 2017 0

Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]

BJBMS Viewpoints

Science in plain words

PD-L1

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

What matters the most when choosing the journal to submit your article?